Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 254 
ORIGINAL ARTICLE
Year : 2017  |  Volume : 23  |  Issue : 2  |  Page : 117-122

Does combining liraglutide with intragastric balloon insertion improve sustained weight reduction?


1 Department of Medicine, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
2 Department of Gastroenterology and Hepatology, Saad Specialist Hospital, Al-Khobar, Kingdom of Saudi Arabia

Correspondence Address:
Mahmoud M Mosli
Department of Medicine, King Abdulaziz University, Jeddah
Kingdom of Saudi Arabia
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1319-3767.203362

Rights and Permissions

Background/Aim: Intragastric balloon (IGB) is an effective and safe method of weight reduction. However, IGBs have been associated with a high rate of weight regain post removal. Accordingly, ways to improve sustained weight reduction including concomitant treatment with Glucagon-like peptide 1 (GLP-1) agonists have been proposed. This study aims to evaluate the effect of adding Liraglutide to IGB insertion on sustained weight reduction. Patients and Methods: A retrospective analysis of all cases treated with IGB with or without Liraglutide was performed. Outcomes were statistically compared. Results: A total of 108 patients were included; 64 were treated with IGB alone and 44 with IGB + Liraglutide. Six months after removing IGB, patients treated with IGB + Liraglutide had a higher mean weight loss post treatment completion (10.2 ± 6.7 vs. 18.5 ± 7.6, P = <0.0001) than those treated with IGB alone. After adjusting for covariates, patients treated with IGB alone demonstrated a higher mean body weight loss at the time of IGB removal (coefficient 7.71, 95% CI = 4.78–10.63), and a higher odds of treatment success 6 months post IGB removal (OR = 5.74, 95% CI = 1.79–188.42). Baseline body mass index appeared to be a significant predictor of mean body weight loss at the time of balloon removal. Conclusions: Adding Liraglutide to IGB does not appear to decrease the risk of weight regain 6 months post IGB removal.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1337    
    Printed14    
    Emailed0    
    PDF Downloaded218    
    Comments [Add]    

Recommend this journal